Drug-Induced Lupus Erythematosus from Injectable Medications

Introduction to DILE

• The American Academy of Dermatology notes that injectable biologics, particularly TNF-α inhibitors like etanercept, can cause drug-induced lupus erythematosus (DILE), with a distinct profile compared to classic DILE 1

Special Considerations for Patients with Pre-existing Autoimmune Disease

• The National Comprehensive Cancer Network recommends that the presence of rheumatoid arthritis or multiple sclerosis does not contraindicate TNF-α inhibitor use, but complicates DILE diagnosis 2
• The National Comprehensive Cancer Network also notes that in patients with pre-existing autoimmune conditions receiving checkpoint inhibitors, 27-42% experienced autoimmune condition flares, though most were manageable 2
• The Centers for Disease Control and Prevention states that vaccination is not contraindicated in patients with autoimmune diseases receiving TNF-α inhibitors, and influenza or hepatitis B vaccination does not increase disease activity or trigger lupus 3
• The Infectious Diseases Society of America recommends that vaccination is safe in patients with autoimmune diseases receiving TNF-α inhibitors, with no increased risk of disease activity or lupus 4

Drug-Induced Lupus Erythematosus

High-Risk Medications

• TNF-α inhibitors (etanercept, adalimumab, infliximab) can cause drug-induced lupus without renal or CNS complications, as documented in dermatology guidelines 5, 6
• Isoniazid can trigger lupus-like syndrome in approximately 20% of patients who develop antinuclear antibodies after treatment 7

Monitoring and Management

• Patients on high-risk medications should be monitored for symptoms such as arthralgia, fever, and pleuritis 8